Stroke: Alteplase improves quality of life

Could cut costs of aftercare – The latest results from the third International Stroke Trial (IST-3) suggest that the drug has the potential to cut costs by reducing the demand for long-term care.

Treatment for acute ischemic stroke (in which blood flow to an area of the brain is blocked or reduced) with alteplase (recombinant tissue plasminogen activator; rtPA) is approved in Europe for patients younger than 80 years within 4.5 hours of symptom onset. Currently, fewer than 15% to 40% of people arrive at the hospital within this treatment window, and only 2% to 5% of suitable patients receive thrombolysis with alteplase.

In 2012, the IST-3 involving 3035 patients (half older than 80 years of age) from 12 countries, reported that those randomly assigned to alteplase treatment within 6 hours of stroke onset had reduced disability at 6 months compared with those who did not receive the drug.

Here, the IST-3 Collaborative Group report the survival, functional outcome, health-related quality of life, and living circumstances of nearly four fifths (2348 patients) of participants from 10 countries* at 18 months.

Although treatment had no effect on survival at 18 months, the odds of being alive and independent were 28% greater for patients given alteplase.

What is more, participants given alteplase reported significantly fewer problems with long-term mobility, self-care, pain and discomfort, and “needing help with everyday activities”.

According to lead author Peter Sandercock from the University of Edinburgh’s Division of Clinical Neurosciences, “In the UK in 2002, the estimated annual cost of long-term care of an independent survivor of stroke and a dependent survivor were £876 and £11 292 respectively, so even a small difference in the proportion of survivors who are able to look after themselves will have substantial economic impact.”

Commenting on the paper, Craig Anderson from The George Institute for Global Health at the University of Sydney, Australia writes, “I commend the IST-3 investigators for providing a more comprehensive, patient-centred approach to assessment of the effects of alteplase on quality of life than has previously been done. Assessment of health-related quality of life helps the interpretation of outcomes and is an important part of decision-making about efficacy of treatment that accounts for the patients’ perspective.”

For further information contact: Peter Sandercock
peter.sandercock@ed.ac.uk

For full Article and Comment: http://press.thelancet.com/alteplase.pdf